Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Last trade$148.68
Day change-$0.175 (-0.12%)
Day range$142.36 – $151.20
Volume678,494
Market cap$16.62B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$16.62B
Price / earnings
65.63×
Price / book
2.29×
Price / sales
5.65×
EV / sales
6.34×
EV / EBITDA
23.76×
Profitability
Earnings per share
$2.27
Return on assets
2.2%
Return on equity
3.48%
Dividend yield
0.19%
Liquidity and leverage
Debt / equity
0.36×
Current ratio
2.65×
Quick ratio
2.1×
Cash ratio
0.85×
Cash flow
Price / cash flow
25.34×
Price / free cash flow
28.14×
Free cash flow
$590.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RVTY, quarterly periods
Line item
Q3 FY2026 Oct 4, 2026
Q2 FY2026 Jul 5, 2026
Q1 FY2026 Apr 5, 2026
Q4 FY2025 Dec 28, 2025
Q3 FY2025 Sep 28, 2025
Q2 FY2025 Jun 29, 2025
Q1 FY2025 Mar 30, 2025
Q4 FY2024 Dec 29, 2024
Revenue
$728.9M
$729.69M
$711.12M
$772.06M
$698.95M
$720.28M
$664.76M
$729.37M
Cost of revenue
$310.32M
$312.82M
$323.46M
$350.4M
$324.35M
$327.73M
$289.22M
$317.08M
Gross profit
$418.58M
$416.87M
$387.66M
$421.66M
$374.6M
$392.56M
$375.55M
$412.29M
Selling, general and administrative
$275.33M
$278.58M
$253.88M
$251.73M
$241.91M
$248.53M
$249.72M
$244.33M
Research and development
$48.11M
$48.97M
$57.89M
$58.18M
$50.8M
$53.27M
$53.6M
$49.21M
Total operating expenses
$323.44M
$327.55M
$311.77M
$309.91M
$292.71M
$301.8M
$303.32M
$293.54M
Operating income
$95.14M
$89.32M
$75.89M
$111.75M
$81.9M
$90.76M
$72.23M
$118.75M
Interest expense
-$17.46M
-$25.79M
-$25.89M
-$20.19M
-$26.21M
-$22.11M
-$19.85M
-$24.19M
Income before taxes
$77.68M
$63.53M
$49.99M
$91.56M
$55.69M
$68.65M
$52.38M
$94.56M
Income taxes
$15.06M
$10.05M
$9.1M
-$4.21M
$8.46M
$13.43M
$10.71M
$6.18M
Net income
$62.3M
$51.82M
$40.72M
$98.36M
$46.65M
$53.95M
$42.24M
$94.65M
Net income attributable to common shareholders
$62.3M
$51.82M
$40.72M
$98.36M
$46.65M
$53.95M
$42.24M
$94.65M
EBITDA
$198.06M
$191.36M
$180.94M
$214.83M
$183.96M
$193.54M
$169.65M
$223.78M
Basic earnings per share
$0.56
$0.47
$0.36
$0.87
$0.40
$0.46
$0.35
$0.78
Diluted earnings per share
$0.56
$0.47
$0.36
$0.87
$0.40
$0.46
$0.35
$0.78
Recent news
Company coverage with links to the original publishers.
In a comparison of two Medical Services stocks, Elevance Health (ELV) and Revvity (RVTY), both holding a Zacks Rank #2 (Buy), ELV emerges as the superior value option. ELV features a lower forward P/E ratio of 14.97 compared to RVTY's 29.34, a better PEG ratio of 2.08 versus 2.79, and a lower P/B ratio of 2.07 versus 2.44. These metrics contribute to ELV's Value grade of A compared to RVTY's C grade.
Revvity (RVTY), a maker of scientific instruments, has been upgraded to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months. The upgrade reflects an improving business outlook, with the stock positioned in the top 20% of Zacks-covered stocks for estimate revisions, suggesting potential near-term upside.
Revvity (RVTY) reported Q3 2026 adjusted EPS of $1.38, beating estimates by 7%, with revenues rising 4.3% to $728.9M. Life Sciences revenues climbed 10.7% driven by strong pharma and biotech demand. The company raised its 2026 pro forma EPS guidance to $5.40-$5.45 and revenue forecast to $2.86B, reflecting 6% total growth and 5% organic growth.
Revvity reported Q3 2026 earnings of $1.38 per share, beating consensus estimates of $1.29, with revenues of $709.61 million slightly exceeding expectations. The company has outperformed the market by 56.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Services industry ranks in the top 40% of Zacks industries.
Cognex is scheduled to report Q3 2026 results on Nov. 4, 2026, with expected revenues of $300-$320 million (12% YoY growth) and adjusted EPS of 50-54 cents (58% YoY growth). The company is expected to benefit from improving industrial demand, AI infrastructure investments, and strong momentum in semiconductor, electronics, packaging, and logistics sectors. However, Cognex has a 0.00% Earnings ESP and Zacks Rank #3, suggesting limited upside surprise potential.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.07 per share
Declared
Oct 30, 2026
Ex-dividend
Jan 22, 2027
Pay date
Feb 12, 2027
Ex-dividend
Amount / share
Pay date
Type
Oct 23, 2026
$0.07
Nov 13, 2026
recurring
Jul 17, 2026
$0.07
Aug 7, 2026
recurring
Apr 17, 2026
$0.07
May 8, 2026
recurring
Jan 16, 2026
$0.07
Feb 6, 2026
recurring
Oct 17, 2025
$0.07
Nov 7, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.